Epigral Q4 Revenue Hits Record ₹736 Cr, Up 17%

Epigral reported record Q4FY26 revenue of ₹736 crore, a 17% YoY increase, with PAT at ₹82 crore.
The Board proposed a final dividend of ₹5 per share and executed ₹394 crore in capex for FY2026.
EBITDA margin improved to 23% in Q4 from 17% in Q3, driven by higher plant utilization and volumes.
Ongoing capacity expansions for CPVC, Epichlorohydrin, and renewable power are on schedule and within budget.